WO2016194692A1 - 抗う蝕剤及び抗う蝕用組成物 - Google Patents
抗う蝕剤及び抗う蝕用組成物 Download PDFInfo
- Publication number
- WO2016194692A1 WO2016194692A1 PCT/JP2016/065242 JP2016065242W WO2016194692A1 WO 2016194692 A1 WO2016194692 A1 WO 2016194692A1 JP 2016065242 W JP2016065242 W JP 2016065242W WO 2016194692 A1 WO2016194692 A1 WO 2016194692A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- cariogenic
- composition
- periodontal disease
- bifidobacteria
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 230000000170 anti-cariogenic effect Effects 0.000 title claims abstract description 59
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 72
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 72
- 239000003795 chemical substances by application Substances 0.000 claims description 64
- 241000894006 Bacteria Species 0.000 claims description 33
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 21
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 20
- 239000004091 cariogenic agent Substances 0.000 claims description 18
- 230000002554 disease preventive effect Effects 0.000 claims description 15
- 239000002270 dispersing agent Substances 0.000 claims description 13
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 230000006806 disease prevention Effects 0.000 claims description 10
- 239000005022 packaging material Substances 0.000 claims description 7
- 239000004075 cariostatic agent Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 28
- 231100000957 no side effect Toxicity 0.000 abstract description 9
- 229920001542 oligosaccharide Polymers 0.000 abstract description 8
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 8
- 150000005846 sugar alcohols Chemical class 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 description 33
- 239000003814 drug Substances 0.000 description 21
- 208000002925 dental caries Diseases 0.000 description 20
- 239000000843 powder Substances 0.000 description 18
- 241001608472 Bifidobacterium longum Species 0.000 description 17
- 229940009291 bifidobacterium longum Drugs 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 239000000902 placebo Substances 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- 208000007565 gingivitis Diseases 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 210000003296 saliva Anatomy 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 230000000675 anti-caries Effects 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000013350 formula milk Nutrition 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000004283 incisor Anatomy 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 229930091371 Fructose Natural products 0.000 description 5
- 239000005715 Fructose Substances 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 5
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000004195 gingiva Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001013 cariogenic effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SVBWNHOBPFJIRU-UHFFFAOYSA-N 1-O-alpha-D-Glucopyranosyl-D-fructose Natural products OC1C(O)C(O)C(CO)OC1OCC1(O)C(O)C(O)C(O)CO1 SVBWNHOBPFJIRU-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Chemical group CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Chemical group 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001746 carotenes Chemical group 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 etc.) Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052587 fluorapatite Inorganic materials 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000002050 maxilla Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000006870 ms-medium Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical group CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- NMXLJRHBJVMYPD-IPFGBZKGSA-N trehalulose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O)CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NMXLJRHBJVMYPD-IPFGBZKGSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Chemical group O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Chemical group 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an anti-cariogenic agent and an anti-cariogenic composition containing bifidobacteria.
- Caries are caused by caries-causing bacteria living in the oral cavity, such as Streptococcus mutans, by ingesting cariogenic carbohydrates such as sucrose, fructose, and glucose contained in food and drink.
- the acid that is produced develops by dissolving the enamel and dentin on the tooth surface.
- tooth surface enamel and dentin are hydroxyapatite and fluoroapatite. These substances are decomposed by the action of acid produced by the above caries-causing bacteria, and phosphate ions and calcium ions are eluted. (Decalcification).
- Patent Document 1 mentions palatinit as a non-cariogenic oligosaccharide that is not assimilated by mutans bacteria.
- Patent Document 2 discloses one or more sugar alcohols selected from xylitol, mannitol, galactitol, and inositol, and describes that they have anti-cariogenic activity.
- an object of the present invention is to provide a new anti-cariogenic agent having no side effect so that an anti-cariogenic effect can be obtained even in humans who are highly sensitive to oligosaccharides and sugar alcohols.
- Another object of the present invention is to provide a periodontal disease preventive agent or a periodontal disease therapeutic agent that has a preventive or therapeutic effect on periodontal disease and has no side effects.
- Bifidobacterium (Bifidobacteria) as a candidate for a new anti-cariogenic agent.
- Bifidobacterium has so far improved diarrhea, constipation, prevention and treatment of opportunistic bacteria and pathogenic microorganisms, inhibition of the growth of harmful bacteria in the intestines, production of B vitamins, digestion and absorption by lactose degradation From the promotion, it was known that it is a useful bacterium in the gut both nutritionally and bacteriologically.
- bifidobacteria have an action on the host intestinal tract immune system and an allergy improving action.
- bifidobacteria have an anti-cariogenic effect alone, and have reached the present invention.
- the present inventors have also found that bifidobacteria alone has a preventive or therapeutic effect on periodontal disease.
- the present invention is as follows. 1. Anti-caries agent containing bifidobacteria. 2. 2. The anti-cariogenic agent according to 1 above, wherein the Bifidobacterium is Bifidobacterium bifidum. 3. 3. The anti-cariogenic agent according to 1 or 2, wherein the Bifidobacterium is Bifidobacterium bifidum OLB6378 strain (Bifidobacterium bifidum OLB6378, accession number: NITE BP-31). 4). 4. The anti-cariogenic agent according to any one of 1 to 3, wherein the bifidobacteria are heat-treated cells. 5. 5. 5.
- An anti-cariogenic composition comprising the anti-cariogenic agent according to any one of 1 to 5 above. 7). Furthermore, the composition for anti-caries of said 6 containing a dispersing agent. 8). 8. The anti-cariogenic composition according to 7 above, wherein the dispersant is dextrin. 9.
- An oral preparation comprising the anti-cariogenic composition described in 10 above.
- 12 11.
- a package comprising the anti-cariogenic composition according to any one of 6 to 10 and a packaging material, wherein the anti-cariogenic composition is packaged in the packaging material.
- 13 Periodontal disease preventive agent or periodontal disease therapeutic agent containing bifidobacteria.
- Heat-treated Bifidobacterium bifidum OLB6378 strain (Bifidobacterium bifidum OLB6378, accession number: NITE BP-31).
- the present invention it is possible to provide a new anti-cariogenic agent or anti-cariogenic composition having no side effects, including bifidobacteria, by finding that it has an anti-cariogenic effect on bifidobacteria.
- bifidobacteria have a preventive or therapeutic effect on periodontal disease
- a new periodontal disease preventive agent or periodontal disease therapeutic agent having no side effects, or a composition for preventing periodontal disease, including bifidobacteria Or a composition for treating periodontal disease can be provided.
- the present invention relates to an anti-cariogenic agent or anti-cariogenic composition containing bifidobacteria. Moreover, this invention relates to the periodontal disease preventive agent or periodontal disease therapeutic agent containing Bifidobacterium, or the composition for periodontal disease prevention, or the composition for periodontal disease treatment.
- the anti-cariogenic agent, periodontal disease preventive agent and periodontal disease therapeutic agent are collectively referred to as “the agent of the present invention”.
- the composition for preventing disease and the composition for treating periodontal disease are collectively referred to as “the composition of the present invention”.
- the bifidobacteria used in the present invention is a bacterium belonging to the genus Bifidobacterium, and there is no restriction on the type or origin thereof. Specifically, for example, Bifidobacterium bifidum, Bifidobacterium longum (Bifidobacterium longum), Bifidobacterium breve (B. breve), Bifidobacterium adrecentis (B Adolescentis), B. infantitis, B. pseudolongum, B. lactis, Bifidobacterium thermos Examples thereof include bifidobacteria such as a film (B. thermophilum).
- Bifidobacterium bifidum examples include Bifidobacterium bifidum OLB6378 strain (Bifidobacterium bifidum OLB6378, accession number: NITE BP-31).
- Bifidobacterium longum for example, Bifidobacterium longum No. 7 strains (Bifidobacterium longum No. 7, accession number: FERM BP-11242), Bifidobacterium longum OLB6290 strain (Bifidobacterium longum OLB6290, accession number: NITE P-75) and the like. By using these strains, the agent of the present invention can be provided.
- the present applicant deposited the Bifidobacterium bifidum OLB6378 strain (Bifidobacterium bifidum OLB6378) under the following conditions.
- Phone number 0438-20-5580 (3) Accession number: NITE BP-31 (4) Display for identification: Bifidobacterium bifidum OLB6378 (5) Date of original deposit: October 26, 2004 (6) Date of transfer to deposit under the Budapest Treaty: January 18, 2006
- Bifidobacterium longum OLB6290 strain (Bifidobacterium longum OLB6290) under the following conditions.
- Phone number 0438-20-5580 (3) Accession number: NITE P-75 (4) Display for identification: Bifidobacterium longum OLB6290 (5) Deposit date: February 3, 2005
- Bifidobacterium bifidum OLB6378 strain Bifidobacterium longum no. Seven strains and Bifidobacterium longum OLB6290 strain have the following mycological properties.
- Bifidobacterium bifidum OLB6378 is a Gram-positive obligate anaerobic bacterium derived from human infant feces. When this strain is coated on a BL agar medium (Eiken Chemical Co., Ltd.) and cultured at 37 ° C for 48 hours under anaerobic conditions using AnaeroPack Kenki (Mitsubishi Gas Chemical), it has an opaque circular hemispherical luster. Form a colony.
- Bifidobacterium bifidum specific primer (intestinal flora symposium 8, molecular ecological detection / identification of intestinal flora, Tomohiro Mitsuoka, Takahiro Matsuki), specifically, a 16S rRNA region species-specific primer, PCR products are observed by PCR using BiBIF-1: CCA CAT GAT CGC ATG TGA TT (SEQ ID NO: 1) and BiBIF-2: CCG AAG GCT TGC TCC CAA A (SEQ ID NO: 2). Moreover, it has fermentability with respect to galactose, glucose, fructose, lactose, and gentiobiose.
- this bacterium is applied on a plate of BL agar medium (Eiken Chemical Co., Ltd.) and cultured at 37 ° C. for 48 hours by the steel wool method, colonies having an opaque circular hemispherical gloss are formed.
- Bifidobacterium longum OLB6290 strain is a Gram-positive obligate anaerobic bacterium derived from human infant feces and has no spore formation.
- PCR was performed with BiLON-1: TTC CAG TTG ATC GCA TGG TC (SEQ ID NO: 3) and BiLON-2: GGG AAG CCG TAT CTC TAC GA (SEQ ID NO: 4), which are species-specific primers of the 16S rRNA region. The PCR product is confirmed.
- a medium usually used for a bifidobacteria medium can be used. That is, the medium that can be used in the present invention is not particularly limited, and any medium can be used as long as it contains a nitrogen source, an inorganic substance, and other nutrients in a predetermined range in addition to the main carbon source.
- lactose glucose, sucrose, fructose, starch hydrolyzate, waste molasses, etc.
- nitrogen source organic nitrogen-containing substances such as casein hydrolyzate, whey protein hydrolyzate, and soy protein hydrolyzate can be used.
- meat extract, fish extract, yeast extract and the like are used as growth promoters.
- Cultivation is preferably performed under anaerobic conditions, and a known method such as a method of culturing while aeration of carbon gas can be applied, but microaerobic conditions such as liquid stationary culture that are usually used, or batch It can also be cultured using other techniques such as culture conditions.
- the culture temperature is preferably 25 to 50 ° C., and particularly preferably 35 to 42 ° C.
- the present invention is not limited to this, and other temperature conditions may be used as long as the bacteria can grow.
- the pH of the culture medium during the culture is preferably maintained at 6.0 to 7.0, but may be other pH conditions as long as the bacteria can grow.
- the culture time is preferably 3 to 48 hours, more preferably 8 to 24 hours, and particularly preferably 10 to 20 hours. However, any other culture time may be used as long as the bacteria can grow.
- the agent of the present invention anticariogenic agent, periodontal disease preventive agent and periodontal disease therapeutic agent
- composition anticariogenic composition, periodontal disease preventive composition and periodontal disease therapeutic composition
- Bifidobacteria is an active ingredient that exhibits the effects of anti-caries, prevention of periodontal disease and treatment of periodontal disease, that is, an active ingredient.
- the obtained microbial cells can be contained in the agent or composition of the present invention as a Bifidobacterium-treated product subjected to the following treatment.
- the treated bifidobacteria the culture after completion of the culture, the culture subjected to centrifugation or filtration after the completion of the culture, the concentrate thereof, further processed into a paste, and dried by various methods ( Spray-dried products, freeze-dried products, vacuum-dried products, drum-dried products, etc.), liquids dispersed in media, dilutions with diluents, heat-treated foods (heat-treated cells), ultraviolet rays and / or radiation Treated with light (treated with light irradiation), treated with medicine (bactericidal agent, antibacterial agent, bacteriostatic agent), crushed material obtained by crushing dried product with a mill , Etc. are included.
- Centrifugation, filtration, concentration, crushing, and the like are performed by commonly used techniques. Drying can be performed by, for example, vacuum drying, spray drying, freeze drying, drum drying, or the like.
- the medium, diluent, drug (bactericidal agent, antibacterial agent, bacteriostatic agent) and the like can be appropriately selected from conventionally known ones. In the present specification, these may be abbreviated as “processed bifidobacteria” or “processed product”.
- the treated product containing the microbial cells of the present invention is not limited to living microbial cells, but is also treated by heat treatment (for example, from a suspension (dispersion) solution of heat-treated bifidobacteria).
- the bifidobacteria and / or processed product obtained by the above method is used as it is as a live or heat-treated bacterium, and then as a crushed or unground product, as a single product or as a mixture of a plurality of types. It can be contained in the agent.
- Live bacteria can be expected to grow in the body (intestines) after ingestion.
- 0.1 ml is sampled from the heat-treated cells (for example, suspension (dispersion) of the heat-treated bifidobacteria), and this is smeared on a petri dish containing a medium in which bifidobacteria can grow, and is subjected to anaerobic conditions. If the colony of the bifidobacteria is not formed even if it is cultured, it is not necessary to consider the characteristics of the bifidobacteria that it is difficult to survive in the presence of oxygen. This is preferable because it expands.
- the bifidobacteria are particularly preferably heat-treated cells that have been heat-treated to form dead cells. It is presumed that the heat treatment of bifidobacteria changes the cell structure of bifidobacteria, making it easier to expose substances that cause anti-caries, periodontal disease prevention and periodontal disease treatment effects. .
- the heating temperature is usually 60 to 300 ° C., preferably 60 ° C. to 200 ° C., more preferably 60 to 150 ° C., further preferably 60 to 140 ° C., further preferably 60 to 130 ° C. More preferably, it is 60 to 120 ° C., more preferably 60 to 110 ° C., further preferably 60 to 100 ° C., more preferably 70 to 100 ° C., further preferably 80 to 100 ° C., and particularly preferably 85 to 95 ° C.
- the temperature of the heat treatment is 60 ° C. or higher because viable bacteria of Bifidobacteria are sterilized.
- the heat treatment is performed at 300 ° C. or lower because the bifidobacteria remain without being carbonized.
- the heat treatment time is usually 0.01 to 120 minutes, preferably 0.015 to 60 minutes, more preferably 0.02 to 40 minutes, still more preferably 0.025 to 30 minutes, still more preferably 0.00. It is 03 to 25 minutes, particularly preferably 0.03 to 20 minutes.
- the heat treatment time it is preferable to set the heat treatment time to 0.01 minutes or more, since the vegetative cells of Bifidobacterium are sterilized. In addition, it is preferable that the heat treatment time is 120 minutes or less because heat denaturation can be suppressed and vegetative cells can be sterilized efficiently.
- the optimum heat treatment time is, for example, 0.2 to 120 minutes, preferably 0.2 to 60 minutes, more preferably 0.2 to 40 minutes in the heat treatment at a low temperature range (60 to 100 ° C.). More preferably, it can be 0.2 to 30 minutes, more preferably 0.2 to 25 minutes, and particularly preferably 0.2 to 20 minutes.
- the heat treatment at a high temperature range for example, 0.01 to 0.5 minutes, preferably 0.015 to 0.5 minutes, more preferably It is 0.02 to 0.5 minutes, more preferably 0.025 to 0.5 minutes, and particularly preferably 0.03 to 0.5 minutes.
- the heat treatment of bifidobacteria is preferably performed at 90 ° C. for 15 minutes.
- the heat treatment method is not particularly limited.
- the obtained microbial cells can be heated under predetermined conditions using a heat sterilizer such as a plate sterilizer, a tubular sterilizer, a direct heating sterilizer, a jacketed tank, or the like.
- the amount of Bifidobacteria to be ingested is, for example, preferably 10 8 or more per day, 10 8 to 10 12 , 5 in order of preference.
- ⁇ 10 8 to 5 ⁇ 10 11 units, 10 9 to 10 11 units, 5 ⁇ 10 9 to 5 ⁇ 10 10 units, 6 ⁇ 10 9 to 4 ⁇ 10 10 units, 7 ⁇ 10 9 to 3 ⁇ 10 10 units is there. More preferably, it is 8 ⁇ 10 9 to 2 ⁇ 10 10 , and even more preferably 9 ⁇ 10 9 to 2 ⁇ 10 10 .
- the agent of the present invention is an ingredient having an effect of anti-caries, periodontal disease prevention and periodontal disease treatment, that is, an active ingredient. As long as it has been found and the effect can be exhibited, there is no limitation on the purpose of use.
- the agent of the present invention since the agent of the present invention has few side effects, it can be taken continuously.
- the ingestion period of the bifidobacteria of the present invention is, for example, 2 to 10 weeks, 2 to 8 weeks, 3 to 7 weeks. 5 to 6.5 weeks, 4 to 6 weeks. Preferably, it is 3.5 to 6.5 weeks, more preferably 4 to 6 weeks.
- an anti-cariogenic effect, a periodontal disease preventive effect, and a periodontal disease therapeutic effect are easily and actually exhibited.
- the agent of the present invention can be used alone, or mixed with other ingredients to be used as an anticaries composition, a periodontal disease-preventing composition or a periodontal disease-treating composition. You can also.
- the compounding amount of the agent of the present invention in the composition can be arbitrarily determined according to its purpose, application, form, dosage form, symptom, body weight and the like.
- the content of the agent of the present invention is 0.01 to 99% (w / w), preferably 0.1 to 90% (w / w) based on the total amount of the composition. ), More preferably 0.1 to 50% (w / w). It is because it becomes easy to ingest (administer) by being in the said range.
- the agent or composition of the present invention can be administered either orally or parenterally (intramuscular, subcutaneous, intravenous, suppository, transdermal, etc.).
- the agent or composition of the present invention can be ingested by adults, but may be infants or elderly people.
- the agent or composition of the present invention can be administered without being affected by such sensitivity, even for humans who are highly sensitive to oligosaccharides or sugar alcohols.
- the agent or composition of the present invention improves diarrhea, improves constipation, prevents and treats opportunistic bacteria and pathogenic microorganisms, suppresses the growth of harmful bacteria in the intestine, produces vitamin B group, decomposes lactose
- it also has anti-cariogenic effect, periodontal disease prevention effect and periodontal disease treatment effect.
- the composition of the present invention can be used in the form of any medicine or food or drink.
- a pharmaceutical product or when taken directly as a special-purpose food or nutritional food such as food for specified health use, an anti-cariogenic effect, a periodontal disease-preventing effect, and a periodontal disease-treating effect may be exhibited.
- special-purpose foods and nutritional foods include prepared milk powder, liquid foods, foods for the sick, foods such as infant milk powder, foods such as infant milk powder, supplements, and nutrition-enriched foods.
- examples of the form include oral administration by preparations such as tablets, coated tablets, capsules, granules, powders, solutions, syrups, and emulsions. These various preparations are applied to the cells and / or processed products of the present invention which are the main agents in accordance with conventional methods, and include dispersants, excipients, binders, disintegrants, lubricants, coloring agents, flavoring agents, and solubilizing aids.
- Can be made into an oral preparation containing an anti-cariogenic pharmaceutical composition by formulating with known adjuvants that can be usually used in the pharmaceutical formulation technical field such as pharmaceuticals, suspensions, and coating agents. .
- oral preparations containing these pharmaceutical compositions contain the agent of the present invention to improve diarrhea, constipation, prevention and treatment of opportunistic bacteria and pathogenic microorganisms, and harmful intestinal Suppresses bacterial growth, promotes production of vitamin B group, promotes digestion and absorption by lactose decomposition, improves host intestinal immunity system, improves allergy, and at the same time has anti-carious effect, teeth Because it has a periodontal disease prevention effect and a periodontal disease treatment effect, it is an effective preparation for various diseases such as diarrhea, constipation, opportunistic bacteria and pathogenic microorganism infections, and diseases caused by proliferation of harmful bacteria in the intestines, It is an effective preparation for caries and periodontal diseases.
- the agent of the present invention is preferably used as a composition mixed with a dispersant.
- the dispersant include milk protein such as casein, soy protein, peptide, amino acid, starch, dextrin, xylan, oligosaccharide, saccharide (glucose, lactose, sucrose, galactose, maltose), sugar alcohol (trehalose, xylitol, erythritol, Palatinose, trehalulose, xylose) and the like.
- dextrin is particularly preferable. This is because by using dextrin as a dispersing agent, the powder can be granulated, handling such as dispersion and dissolution is easy, and long-term storage is possible.
- the shape of the dispersant, particularly dextrin is preferably a granule. This is because the granule is not only highly soluble but also has high filling performance, and can be packaged in a small amount. Moreover, it is because it has the manufacturing advantage of enabling accurate packaging with no variation in mass distribution simply by dropping and packaging the packaging material.
- the mass ratio of the agent of the present invention to the dispersant is preferably 1: 100 to 1: 2, more preferably 1: 100 to 1:10, and still more preferably 1: 100. ⁇ 1: 20. It is because the agent of the present invention can be efficiently dispersed by setting the mass ratio of the agent of the present invention to the dispersant within the above range.
- the composition of the present invention containing the agent of the present invention and a dispersant (particularly dextrin) is orally administered
- the composition of the present invention is subdivided into predetermined amounts and packaged in a packaging material.
- Can then be administered That is, the composition can be administered after a predetermined amount of the composition of the present invention and a packaging material, and the composition is packaged in a package.
- agent and composition of the present invention are added to an anti-cariogenic food composition having no side effects, various foods and beverages (milk, soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crust, preparation Powdered milk, liquid food, food for the sick, food such as infant milk powder, food such as milk powder for nursing women, nutritional food, etc.)
- the agent and composition of the present invention can be used as they are, or can be used according to a conventional method for ordinary food compositions such as mixing with other foods or food ingredients.
- the properties may be in the state of foods and drinks that are usually used, for example, solid (powder, granule, etc.), paste, liquid or suspension.
- solid (powder, granule, etc.) paste, liquid or suspension.
- agent and composition of the present invention may be used as a composition in which water, protein, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like are mixed without causing side effects. it can.
- proteins include whole milk powder, skim milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, ⁇ -lactoglobulin , ⁇ -lactalbumin, lactoferrin, soy protein, chicken egg protein, meat protein and other animal and plant proteins, hydrolysates thereof; butter, milk minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose, etc. And various milk-derived components. Proteins without side effects and various milk-derived components that have been used as pharmaceuticals and foods and drinks are all applicable. Moreover, these components can be used in combination of 2 or more types.
- saccharide examples include saccharides, processed starch (in addition to dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
- lipid examples include animal oils such as lard, fish oil, etc., fractionated oils, hydrogenated oil, transesterified oil, etc .; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples include vegetable oils such as hydrogenated oils and transesterified oils.
- vitamins examples include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline. And folic acid.
- minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and the like.
- organic acid examples include malic acid, citric acid, lactic acid, and tartaric acid. All drugs that have been used as pharmaceuticals and foods and have no side effects are applicable. Moreover, these components can be used in combination of 2 or more types.
- the production method can be performed by methods well known to those skilled in the art. If it is an expert, the process which mixes the bifidobacteria or processed material of this invention with another component, a shaping
- the agent of the present invention can be applied to health functional foods and sick foods.
- the health functional food system was established not only for regular foods but also for foods in the form of tablets, capsules, etc., based on domestic and foreign trends and consistency with the conventional food system for specified health use. It consists of two types of food for specified health use (individual permission type) and functional food for nutrition (standard type). It is expected to exert an anti-cariogenic effect when taken directly as a special-purpose food such as a food for specified health use or a nutritional functional food containing the agent or composition of the present invention.
- Example 1 (Preparation of bifidobacteria) Bifidobacterium bifidum OLB 6378 (accession number: NITE BP-31) was cultured overnight at 37 ° C. in an anaerobic EG medium prepared with the composition shown in Table 1.
- Example 2 (Preparation of the agent of the present invention) a) Preparation of freeze-dried powder of OLB6378 strain subjected to heat treatment: Raw material obtained by adjusting 180 g of the original bacterial powder (live cell count, 3.9 ⁇ 10 11 cfu / g) of OLB6378 strain obtained in Example 1 to 45 ° C. Suspended completely in 2800 ml of water with stirring. Then, it heated with stirring, hold
- Test Example 1 In Test Example 1, the group of subjects who took the agent of Example 2 was referred to as “the agent-taking group of the present invention”, and the group of subjects who took the placebo of Comparative Example 1 was referred to as the “placebo-taking group”. A group of 30 subjects was selected for both groups according to the criteria for selecting and excluding subjects to be described later. Of these, 15 were taken as the group taking the agent of the present invention and 15 were taken as the placebo. Both groups took the agent of Example 2 or the placebo of Comparative Example 1 twice a day. The intake period is 5 weeks. Both groups were evaluated according to the evaluation items described later.
- Exclusion criteria for subjects corresponded to at least one of the following a) to j). a) A person who was determined to have caries (C3 or higher) or severe periodontal disease at the time of screening test b) suffers from diabetes, chronic kidney disease, gastrointestinal disorder, lung disease, malignant tumor, etc.
- the number of mutans and streptococci in the saliva was measured by a culture method.
- the caries bacteria ratio was calculated respectively.
- the caries bacteria ratio was calculated on the intake start date, 4 weeks and 5 weeks after the start of intake.
- the number of streptococci is on Mitis-Salivarius agar medium (MS medium)
- the number of mutans is on an agar medium (MSB medium) obtained by adding Bacitracin (SIGMA) to Mitis-Salivarius agar medium.
- SIGMA Bacitracin
- Gingivitis index is an index as to whether or not the agent of the present invention has a periodontal disease preventive effect and a periodontal disease treatment effect. J., Acta Odontologica Scandinavica 1963 21: 533-51). Specifically, a total of 24 tooth surfaces on the lingual side, lip side / cheek side, mesial side, and distal side of six teeth at predetermined locations were visually confirmed and measured by the following evaluation criteria and evaluation method.
- the six teeth at the predetermined locations are the maxillary right first molar, maxillary left central incisor, maxillary left first premolar, mandibular left first premolar, mandibular right central incisor, mandibular right first premolar. Of 6 teeth.
- plaque index is an index as to whether or not the agent of the present invention has a periodontal disease preventive effect and a periodontal disease treatment effect, and is described in Non-Patent Document 2 (Comparative cleaning of manual and power brushing. Quigley H). , Hein JN., J Am Dent Ass 1962 65:26). Specifically, a total of 24 tooth surfaces on the lingual side, lip side / cheek side, mesial side, and distal side of six teeth at predetermined locations were visually confirmed and measured by the following evaluation criteria and evaluation method.
- the six teeth at the predetermined locations are the maxillary right first molar, maxillary left central incisor, maxillary left first premolar, mandibular left first premolar, mandibular right central incisor, mandibular right first premolar. Of 6 teeth.
- plaque index (total plaque evaluation of each tooth) / (number of teeth to be examined)
- Gingivitis index In the group taking the agent of the present invention, the average gingivitis index on the day of ingestion was 0.13, whereas the average gingivitis index after 5 weeks was significantly reduced to 0.04. On the other hand, in the placebo ingestion group, the average gingivitis index on the day of ingestion was 0.21, whereas the average gingivitis index after 5 weeks was not significantly decreased to 0.505.
- statistical analysis compare between both groups is a Wilcoxon rank sum test, comparison between each group before and after the intake period is a Wilcoxon signed rank test. As a result, the p value on the screening day was 0.378, and the p value after 5 weeks was 0.065.
- the agent of the present invention since the significant reduction in the caries ratio was observed only in the group taking the present invention and not in the placebo group, the agent of the present invention has an anti-cariogenic effect. I understood. In addition, since the significant decrease in the gingivitis index and the prevention of the deterioration of the plaque index were observed only in the group taking the agent of the present invention and not in the group taking the placebo, the agent of the present invention was effective in preventing periodontal disease and It was found to have a therapeutic effect on peri-disease.
- a new anti-cariogenic agent or anti-cariogenic composition having no side effects including bifidobacteria.
- a new periodontal disease preventive agent or periodontal disease therapeutic agent containing bifidobacteria or a composition for periodontal disease prevention or a composition for periodontal disease treatment that has no side effects.
- Bifidobacteria can reduce the caries ratio in the oral cavity, and as a result, can prevent and treat caries.
- bifidobacteria can reduce the symptom of gingivitis and can reduce the adhesion of plaque to the teeth. As a result, periodontal disease can be prevented and treated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
また、歯周病の予防効果又は治療効果が得られ、かつ副作用のない歯周病予防剤又は歯周病治療剤を提供することにある。
1.ビフィズス菌を含む抗う蝕剤。
2.前記ビフィズス菌がビフィドバクテリウム・ビフィダム(Bifidobacterium bifidum)である前記1に記載の抗う蝕剤。
3.前記ビフィズス菌がビフィドバクテリウム・ビフィダムOLB6378菌株(Bifidobacterium bifidum OLB6378、受託番号:NITE BP-31)である前記1又は2に記載の抗う蝕剤。
4.前記ビフィズス菌が加熱処理された菌体である、前記1~3のいずれか1に記載の抗う蝕剤。
5.一日当たり108個以上の菌数の前記ビフィズス菌を4週間以上連続して適用される前記1~4のいずれか1に記載の抗う蝕剤。
6.前記1~5のいずれか1項に記載の抗う蝕剤を含有する抗う蝕用組成物。
7.さらに分散剤を含有する、前記6に記載の抗う蝕用組成物。
8.前記分散剤がデキストリンである、前記7に記載の抗う蝕用組成物。
9.前記抗う蝕用組成物が抗う蝕用食品組成物である前記6~8のいずれか1に記載の抗う蝕用組成物。
10.前記抗う蝕用組成物が抗う蝕用医薬組成物である前記6~8のいずれか1に記載の抗う蝕用組成物。
11.前記10に記載の抗う蝕用組成物を含有する経口用製剤。
12.前記6~10のいずれか1に記載の抗う蝕用組成物と包材を含み、該抗う蝕用組成物が包材内に包装される、包装体。
13.ビフィズス菌を含む歯周病予防剤又は歯周病治療剤。
14.ビフィズス菌を含む抗う蝕剤、歯周病予防剤又は歯周病治療剤。
15.加熱処理されたビフィドバクテリウム・ビフィダムOLB6378菌株(Bifidobacterium bifidum OLB6378、受託番号:NITE BP-31)。
本発明は、ビフィズス菌を含む抗う蝕剤又は抗う蝕用組成物に関する。
また、本発明は、ビフィズス菌を含む歯周病予防剤もしくは歯周病治療剤、又は歯周病予防用組成物もしくは歯周病治療用組成物に関する。
本発明に使用されるビフィズス菌は、ビフィドバクテリウム属に属する細菌であり、その種類や由来に制限がない。具体的には、例えば、ビフィドバクテリウム・ビフィダム(Bifidobacterium bifidum)、ビフィドバクテリウム・ロンガム(Bifidobacterium longum)、ビフィドバクテリウム・ブレーベ(B.breve)、ビフィドバクテリウム・アドレセンティス(B.adolescentis)、ビフィドバクテリウム・インファンティス(B.infantis)、ビフィドバクテリウム・シュードロンガム(B.pseudolongum)、ビフィドバクテリウム・ラクティス(B.lactis)、ビフィドバクテリウム・サーモフィルム(B.thermophilum)等のビフィズス菌が挙げられる。
(1)寄託機関名:独立行政法人製品評価技術基盤機構 特許微生物寄託センター
(2)連絡先:〒292-0818 千葉県木更津市かずさ鎌足2-5-8(現:千葉県木更津市かずさ鎌足2-5-8 122号室)
電話番号0438-20-5580
(3)受託番号:NITE BP-31
(4)識別のための表示:Bifidobacterium bifidum OLB6378
(5)原寄託日:2004年10月26日
(6)ブダペスト条約に基づく寄託への移管日:2006年1月18日
(1)寄託機関名:独立行政法人産業技術総合研究所(現:国立研究開発法人産業技術総合研究所) 特許生物寄託センター
(現寄託機関名:独立行政法人製品評価技術基盤機構 特許生物寄託センター)
(2)連絡先:〒305-8566 茨城県つくば市東1-1-1 中央第6
電話番号029-861-6029
(現連絡先:〒292-0818 千葉県木更津市かずさ鎌足2-5-8 120号室
電話番号0438-20-5910)
(3)受託番号:FERM BP-11242
(4)識別のための表示:Bifidobacterium longum No.7
(5)原寄託日:平成5年4月20日
(6)ブダペスト条約に基づく寄託への移管日:2010年3月2日
(1)寄託機関名:独立行政法人製品評価技術基盤機構 特許微生物寄託センター
(2)連絡先:〒292-0818 千葉県木更津市かずさ鎌足2-5-8(現:千葉県木更津市かずさ鎌足2-5-8 122号室)
電話番号0438-20-5580
(3)受託番号:NITE P-75
(4)識別のための表示:Bifidobacterium longum OLB6290
(5)寄託日:平成17年2月3日
本明細書ではこれらを、「ビフィズス菌処理物」又は「処理物」と略記することがある。
Bifidobacterium bifidum OLB 6378株(受託番号:NITE BP-31)を、表1に示す組成で調製した嫌気EG培地で37℃にて一夜培養した。
a)加熱処理したOLB6378株の凍結乾燥粉末の調製
実施例1で得られたOLB6378株の原菌末(生菌数、3.9×1011cfu/g)180gを、45℃に調整した原料水2800mlに撹拌しながら完全に懸濁させた。その後、撹拌しながら加温して、90℃15分間保持し、冷却した。得られた加熱菌体の懸濁液を凍結乾燥し、加熱処理したOLB6378株の凍結乾燥粉末156gを得た。なお、加熱処理したOLB6378株にはMRS寒天平板培地上でビフィズス菌の生菌は見られなかった。また、得られたOLB6378株の凍結乾燥粉末156g中には、概算して、7.02×1013個の菌数のビフィズス菌が存在する(3.9×1011(cfu/g)×180(g)=7.02×1013cfu)。熱処理された菌体数は、生菌数(cfu)に換算して示されている。
加熱処理したOLB6378株の凍結乾燥粉末120gと顆粒デキストリン(松谷化学社)2880gを均一に混合し、各1gずつ分包し、本発明の剤とした。この本発明の剤には、概算して、1.8×1010個の菌数のビフィズス菌が存在する(7.02×1013(cfu)/156(g)×120/3000(g)=1.8×1010cfu)。熱処理された菌体数は、生菌数(cfu)に換算して示されている。
実施例2の剤の代わりに、顆粒デキストリン(松谷化学社)3000gを、各1gずつ分包し、比較例1のプラセボとした。
試験例1では、実施例2の剤を摂取した被験者群を「本発明の剤摂取群」とし、比較例1のプラセボを摂取した被験者群を「プラセボ摂取群」とした。被験者群は、後述する被験者の選択基準及び除外基準に従い、両群あわせて30名選定した。このうち、本発明の剤摂取群を15名、プラセボ摂取群を15名とした。両群はいずれも一日二回、実施例2の剤又は比較例1のプラセボを摂取した。摂取期間は5週間である。両群の評価は、後述する評価項目に従って行った。
被験者の選択基準は、以下のA)~E)のすべてに該当するものとした。
A)20歳以上40歳以下の女性
B)通常1日に3回食事を摂取する者
C)FDI歯コード16(上顎右側第1大臼歯)、21(上顎左側中切歯)、24(上顎左側第1小臼歯)、36(下顎左側第1大臼歯)、41(下顎右側中切歯)、44(下顎右側第1小臼歯)の6歯の唇側・頬側面のうち、4歯以上が測定可能な者。前記の6代表歯の代替としてFDI歯コード17,15,11,22,25,37,35,31,42,45が存在する者
D)スクリーニング検査時に、う蝕及び歯周疾患の治療を受けておらず、歯が20本以上存在する者
E)試験の目的・内容について十分な説明を受け、同意能力があり、よく理解した上で自発的に参加を志願し、書面で試験参加に同意した者
被験者の除外基準は、以下のa)~j)の少なくとも1に該当するものとした。
a)スクリーニング検査時に、う蝕(C3以上)又は重度の歯周疾患と判断された者
b)糖尿病、慢性腎臓病、胃腸障害、肺疾患、悪性腫瘍等に罹患し、薬剤を服用している者
c)他の医薬品や食品の試験等に現在参加中の者、参加の意志のある者
d)5分間の刺激唾液量が3.0ml以下の者
e)刺激唾液のpHが6.2以下の者
f)可撤性義歯を装着している者
g)スクリーニング検査前1ヶ月以内に、洗口剤、抗生物質、抗菌剤を使用した者、及び歯科を受診した者
h)食物アレルギーを有する者
i)妊娠している者、試験期間中に妊娠の意思がある者、授乳中の者
j)その他、試験責任歯科医師が被験者として不適当と判断した者
1.う蝕菌比率
う蝕菌比率は、本発明の剤が抗う蝕効果を有するか否かの指標となるもので、唾液中のレンサ球菌に占めるミュータンス菌数の割合を示す。すなわち、う蝕菌比率は以下の式で表される。
う蝕菌比率=(ミュータンス菌数/レンサ球菌数)×100
歯肉炎指数は、本発明の剤が歯周病予防効果及び歯周病治療効果を有するか否かの指標となるもので、非特許文献1(Periodontal disease in pregnancy. Lee H,Silness J.,Acta Odontologica Scandinavica 1963 21:533-51)に記載の方法に沿って測定を行った。具体的には、所定箇所の6歯の舌側、唇側・頬側、近心側、遠心側の合計24歯面を目視により確認し、下記の評価基準及び評価方法で測定した。なお、上記所定箇所の6歯とは、上顎右側第1大臼歯、上顎左側中切歯、上顎左側第1小臼歯、下顎左側第1大臼歯、下顎右側中切歯、下顎右側第1小臼歯の6歯を指す。
0:臨床的に正常な歯肉。
1:軽度の炎症、歯肉のわずかな色調変化があるもので、プローブによる歯肉辺縁内縁部の擦過により出血が認められない。
2:中等度の炎症、歯肉に発赤を伴う浮腫と光沢があり、歯肉辺縁内縁部の擦過により出血が認められる。
3:高度の炎症、著しい発赤、浮腫があり、自然出血、潰瘍形成がある。
被験者らの刺激唾液(ガムを噛んで出る唾液)を5分間採取した後、歯科医師による問診と口腔診断を行った記録から、歯肉炎指数を算出した。歯肉炎指数は、下記の式により算出し、スクリーニング日(摂取開始日の1ヶ月前)及び摂取開始から5週間後に行った。
(歯肉炎指数)=(各歯の歯肉炎評価の合計)/(被検歯面数)
プラーク指数は、本発明の剤が歯周病予防効果及び歯周病治療効果を有するか否かの指標となるもので、非特許文献2(Comparative cleaning efficiency of manual and power brushing.Quigley H,Hein JN.,J Am Dent Ass 1962 65:26)に記載の方法に沿って測定を行った。具体的には、所定箇所の6歯の舌側、唇側・頬側、近心側、遠心側の合計24歯面を目視により確認し、下記の評価基準及び評価方法で測定した。なお、上記所定箇所の6歯とは、上顎右側第1大臼歯、上顎左側中切歯、上顎左側第1小臼歯、下顎左側第1大臼歯、下顎右側中切歯、下顎右側第1小臼歯の6歯を指す。
0:プラークの付着が認められない。
1:歯肉縁に沿ってプラークが点状に存在。
2:歯肉縁に沿ってプラークが線状に存在。
3:歯面の歯肉側3分の1以内にプラークが存在。
4:歯面の歯肉側3分の2以内にプラークが存在。
5:歯面の歯肉側3分の2以上にプラークが存在。
被験者の刺激唾液(ガムを噛んで出る唾液)を5分間採取した後、歯科医師による問診と口腔診断を行った記録から、プラーク指数を算出した。プラーク指数は、下記の式により算出し、スクリーニング日(摂取開始日の1ヶ月前)及び摂取開始から5週間後に行った。
(プラーク指数)=(各歯のプラーク評価の合計)/(被検歯面数)
1.う蝕菌比率
本発明の剤摂取群では、摂取開始日のう蝕菌比率の平均が0.5であったのに対し、4週間後のう蝕菌比率の平均は0.2と有意に低下した。一方、プラセボ摂取群では、摂取開始日のう蝕菌比率の平均が0.2であったのに対し、4週間後のう蝕菌比率の平均は0.2と有意な変化はなかった。
なお、本発明の剤摂取群とプラセボ摂取群の両群間の比較として、統計解析(両群間の比較はWilcoxon順位和検定、各群の摂取期間前後の比較はWilcoxon符号付順位検定)を行ったところ、摂取開始日のp値は0.218、4週間後のp値は0.973であった。
本発明の剤摂取群では、摂取開始日の歯肉炎指数の平均が0.13であったのに対し、5週間後の歯肉炎指数の平均は0.04と有意に低下した。一方、プラセボ摂取群では、摂取開始日の歯肉炎指数の平均が0.21であったのに対し、5週間後の歯肉炎指数の平均は0.505と有意な低下は見られなかった。
なお、本発明の剤摂取群とプラセボ摂取群の両群間の比較として、統計解析(両群間の比較はWilcoxon順位和検定、各群の摂取期間前後の比較はWilcoxon符号付順位検定)を行ったところ、スクリーニング日のp値は0.378であり、5週間後のp値は0.065であった。
本発明の剤摂取群では、摂取開始日のプラーク指数の平均が0.17であったのに対し、5週間後のプラーク指数の平均は0.17と有意な上昇は見られなかった。一方、プラセボ摂取群では、摂取開始日のプラーク指数の平均が0.17であったのに対し、5週間後のプラーク指数の平均は0.33と有意な高い値となった。
なお、本発明の剤摂取群とプラセボ摂取群の両群間の比較として、統計解析(両群間の比較はWilcoxon順位和検定、各群の摂取期間前後の比較はWilcoxon符号付順位検定)を行ったところ、スクリーニング日のp値は0.849であり、5週間後のp値は0.043であった。
また、歯肉炎指数の有意な低下とプラーク指数の悪化防止が、本発明の剤摂取群のみで認められプラセボ摂取群では認められなかったことから、本発明の剤は歯周病予防効果及び歯周病治療効果を有していることが分かった。
Claims (12)
- ビフィズス菌を含む抗う蝕剤。
- 前記ビフィズス菌がビフィドバクテリウム・ビフィダム(Bifidobacterium bifidum)である請求項1に記載の抗う蝕剤。
- 前記ビフィズス菌がビフィドバクテリウム・ビフィダムOLB6378菌株(Bifidobacterium bifidum OLB6378、受託番号:NITE BP-31)である請求項1又は2に記載の抗う蝕剤。
- 前記ビフィズス菌が加熱処理された菌体である、請求項1~3のいずれか1項に記載の抗う蝕剤。
- 一日当たり108個以上の菌数の前記ビフィズス菌を4週間以上連続して適用される請求項1~4のいずれか1項に記載の抗う蝕剤。
- 請求項1~5のいずれか1項に記載の抗う蝕剤を含有する抗う蝕用組成物。
- さらに分散剤を含有する、請求項6に記載の抗う蝕用組成物。
- 前記分散剤がデキストリンである、請求項7に記載の抗う蝕用組成物。
- 請求項6~8のいずれか1項に記載の抗う蝕用組成物と包材を含み、該抗う蝕用組成物が包材内に包装される、包装体。
- ビフィズス菌を含む歯周病予防剤又は歯周病治療剤。
- ビフィズス菌を含む抗う蝕剤、歯周病予防剤又は歯周病治療剤。
- 加熱処理されたビフィドバクテリウム・ビフィダムOLB6378菌株(Bifidobacterium bifidum OLB6378、受託番号:NITE BP-31)。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2980102A CA2980102A1 (en) | 2015-05-29 | 2016-05-24 | Anticariogenic agent and anticariogenic composition |
CN201680017686.2A CN107530382B (zh) | 2015-05-29 | 2016-05-24 | 防龋剂和防龋组合物 |
JP2017521832A JP6865682B2 (ja) | 2015-05-29 | 2016-05-24 | 抗う蝕剤及び抗う蝕用組成物 |
SG11201707793YA SG11201707793YA (en) | 2015-05-29 | 2016-05-24 | Anticariogenic agent and anticariogenic composition |
US15/560,375 US20180071346A1 (en) | 2015-05-29 | 2016-05-24 | Anticariogenic agent and anticariogenic composition |
MYPI2017703463A MY188694A (en) | 2015-05-29 | 2016-05-24 | Anticariogenic agent and anticariogenic composition |
EP16803127.6A EP3305309A4 (en) | 2015-05-29 | 2016-05-24 | ANTI-CARIOGEN AGENT AND ANTI-CARIOGEN COMPOSITION |
HK18103064.5A HK1243634A1 (zh) | 2015-05-29 | 2018-03-02 | 防齲劑和防齲組合物 |
US16/353,678 US10517907B2 (en) | 2015-05-29 | 2019-03-14 | Anticariogenic agent and anticariogenic composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015110743 | 2015-05-29 | ||
JP2015-110743 | 2015-05-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/560,375 A-371-Of-International US20180071346A1 (en) | 2015-05-29 | 2016-05-24 | Anticariogenic agent and anticariogenic composition |
US16/353,678 Continuation US10517907B2 (en) | 2015-05-29 | 2019-03-14 | Anticariogenic agent and anticariogenic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016194692A1 true WO2016194692A1 (ja) | 2016-12-08 |
Family
ID=57441489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/065242 WO2016194692A1 (ja) | 2015-05-29 | 2016-05-24 | 抗う蝕剤及び抗う蝕用組成物 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180071346A1 (ja) |
EP (1) | EP3305309A4 (ja) |
JP (1) | JP6865682B2 (ja) |
CN (1) | CN107530382B (ja) |
CA (1) | CA2980102A1 (ja) |
HK (1) | HK1243634A1 (ja) |
MY (1) | MY188694A (ja) |
SG (1) | SG11201707793YA (ja) |
TW (1) | TWI705135B (ja) |
WO (1) | WO2016194692A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019117212A1 (ja) * | 2017-12-12 | 2019-06-20 | 森永乳業株式会社 | ビフィドバクテリウム属細菌を有効成分とする組成物 |
US11617369B2 (en) | 2018-02-26 | 2023-04-04 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Antimicrobial gallium compounds and methods |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3810161A1 (en) * | 2018-06-22 | 2021-04-28 | Synformulas GmbH | Non-viable bifidobacterium bifidum bacteria and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003171292A (ja) * | 2001-11-29 | 2003-06-17 | Biofuerumin Seiyaku Kk | 歯周病の予防または治療剤 |
WO2006087913A1 (ja) * | 2005-02-02 | 2006-08-24 | Meiji Dairies Corporation | 免疫賦活用組成物 |
WO2007020884A1 (ja) * | 2005-08-12 | 2007-02-22 | Meiji Dairies Corporation | β-ディフェンシンを介した感染予防効果を有するビフィズス菌または乳酸菌とそれを含有する食品・医薬品組成物 |
JP2008182931A (ja) * | 2007-01-29 | 2008-08-14 | Meiji Milk Prod Co Ltd | 歯周病原因菌の除菌用微生物及び当該微生物を含有する歯周病予防又は治療のための医薬組成物、食品又は食品添加物 |
JP2011201840A (ja) * | 2010-03-26 | 2011-10-13 | Meiji Co Ltd | 少容量に充填したプロバイオティクス含有組成物 |
JP2012526752A (ja) * | 2009-05-11 | 2012-11-01 | ネステク ソシエテ アノニム | ビフィドバクテリウム・ロンガムncc2705(cncmi−2618)及び免疫障害 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1112143A (ja) | 1997-06-20 | 1999-01-19 | Lion Corp | 口腔用組成物 |
JP2000281550A (ja) | 1999-03-31 | 2000-10-10 | Sunstar Inc | 口腔用組成物 |
US20060018843A1 (en) * | 2004-07-24 | 2006-01-26 | Fine Kenneth D | Halitosis, gingivitis, and periodontitis treatment and preventative composition |
RU2558934C1 (ru) * | 2014-05-12 | 2015-08-10 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ОИС УрО РАН) | Средство для фиксации съемных зубных протезов |
RU2580615C1 (ru) * | 2015-06-08 | 2016-04-10 | Зухра Фаниловна Эделева | Способ лечения пародонтита |
-
2016
- 2016-05-24 MY MYPI2017703463A patent/MY188694A/en unknown
- 2016-05-24 SG SG11201707793YA patent/SG11201707793YA/en unknown
- 2016-05-24 JP JP2017521832A patent/JP6865682B2/ja active Active
- 2016-05-24 CN CN201680017686.2A patent/CN107530382B/zh active Active
- 2016-05-24 CA CA2980102A patent/CA2980102A1/en active Pending
- 2016-05-24 WO PCT/JP2016/065242 patent/WO2016194692A1/ja active Application Filing
- 2016-05-24 TW TW105116068A patent/TWI705135B/zh active
- 2016-05-24 US US15/560,375 patent/US20180071346A1/en not_active Abandoned
- 2016-05-24 EP EP16803127.6A patent/EP3305309A4/en active Pending
-
2018
- 2018-03-02 HK HK18103064.5A patent/HK1243634A1/zh unknown
-
2019
- 2019-03-14 US US16/353,678 patent/US10517907B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003171292A (ja) * | 2001-11-29 | 2003-06-17 | Biofuerumin Seiyaku Kk | 歯周病の予防または治療剤 |
WO2006087913A1 (ja) * | 2005-02-02 | 2006-08-24 | Meiji Dairies Corporation | 免疫賦活用組成物 |
WO2007020884A1 (ja) * | 2005-08-12 | 2007-02-22 | Meiji Dairies Corporation | β-ディフェンシンを介した感染予防効果を有するビフィズス菌または乳酸菌とそれを含有する食品・医薬品組成物 |
JP2008182931A (ja) * | 2007-01-29 | 2008-08-14 | Meiji Milk Prod Co Ltd | 歯周病原因菌の除菌用微生物及び当該微生物を含有する歯周病予防又は治療のための医薬組成物、食品又は食品添加物 |
JP2012526752A (ja) * | 2009-05-11 | 2012-11-01 | ネステク ソシエテ アノニム | ビフィドバクテリウム・ロンガムncc2705(cncmi−2618)及び免疫障害 |
JP2011201840A (ja) * | 2010-03-26 | 2011-10-13 | Meiji Co Ltd | 少容量に充填したプロバイオティクス含有組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3305309A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019117212A1 (ja) * | 2017-12-12 | 2019-06-20 | 森永乳業株式会社 | ビフィドバクテリウム属細菌を有効成分とする組成物 |
JPWO2019117212A1 (ja) * | 2017-12-12 | 2020-12-03 | 森永乳業株式会社 | ビフィドバクテリウム属細菌を有効成分とする組成物 |
US11617369B2 (en) | 2018-02-26 | 2023-04-04 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Antimicrobial gallium compounds and methods |
Also Published As
Publication number | Publication date |
---|---|
HK1243634A1 (zh) | 2018-07-20 |
TWI705135B (zh) | 2020-09-21 |
JPWO2016194692A1 (ja) | 2018-03-22 |
US10517907B2 (en) | 2019-12-31 |
SG11201707793YA (en) | 2017-10-30 |
CN107530382A (zh) | 2018-01-02 |
EP3305309A1 (en) | 2018-04-11 |
EP3305309A4 (en) | 2019-02-13 |
TW201713766A (zh) | 2017-04-16 |
MY188694A (en) | 2021-12-23 |
JP6865682B2 (ja) | 2021-04-28 |
CA2980102A1 (en) | 2016-12-08 |
US20180071346A1 (en) | 2018-03-15 |
CN107530382B (zh) | 2021-07-27 |
US20190201460A1 (en) | 2019-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7088829B2 (ja) | 新生児向けの脳機能改善用組成物 | |
CN103298924A (zh) | 用于口腔健康的益生菌组合物 | |
CN104277998A (zh) | 用于预防和/或治疗口腔恶臭的用途和方法 | |
US20040146493A1 (en) | Use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries | |
JP6849972B2 (ja) | 乳児向けの感染防御剤 | |
US10517907B2 (en) | Anticariogenic agent and anticariogenic composition | |
JP6285687B2 (ja) | 口腔内疾患予防剤 | |
TW202022109A (zh) | 新穎乳酸菌株及包含新穎乳酸菌株之免疫賦活劑 | |
Lin et al. | Inhibitory effect of Lactobacillus paracasei subsp. paracasei NTU 101 on rat dental caries | |
WO2018190407A1 (ja) | Toll様受容体2活性化用組成物 | |
JP6823302B2 (ja) | 乳児向けの抗アレルギー剤 | |
TWI745454B (zh) | 抑制腸道內乳桿菌屬乳酸菌減少用之組成物 | |
WO2023282356A1 (ja) | 口腔用組成物、および口腔内疾患の予防または治療方法 | |
JP2022157465A (ja) | 乳幼児用排便促進剤 | |
Nadelman et al. | The effect of probiotics on oral health | |
WO2024117190A1 (ja) | 口腔内環境又は歯茎の健康を維持するための組成物 | |
GS | Comparative Evaluation of the Efficacy of the Probiotic, Chlorhexidineand Fluoride Mouthwash Against Salivary Streptococcus Mutans-An in Vivo Study | |
Narula | Probiotics: A New Approach To Oral Health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16803127 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2980102 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2016803127 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15560375 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2017521832 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201707793Y Country of ref document: SG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |